Announcements Trials

Browse Landscape

Phase

Phase 1 3 Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Lymphoid 1 Gynecologic 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 72 Paclitaxel 63 Cyclophosphamide 56 pembrolizumab 52 Fulvestrant 42 Carboplatin 39 Capecitabine 37 Docetaxel 32 Letrozole 27 Doxorubicin 23 palbociclib 21 pertuzumab 20 Nivolumab 18 eribulin 17 abemaciclib 17 ribociclib 16 Gemcitabine 16 130-nm albumin-bound paclitaxel 16 durvalumab 15 Everolimus 15 Albumin-Bound Paclitaxel 15 sacituzumab govitecan 14 Lapatinib 14 Filgrastim 14 fludarabine 13 exemestane 13 Taxes 13 Bevacizumab 13 Cisplatin 12 olaparib 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × vistusertib × Breast × Clear all

NCT02583542 2020-02-25

TORCMEK

Queen Mary University of London

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡